The TyG index, as a surrogate marker of IR, reflects underlying metabolic dysregulation, including impaired insulin signaling in target tissues and compensatory hyperinsulinemia, which are key drivers of adverse outcomes in critically ill patients (35, 36). This evidence concerns the gene INS and Hyperinsulinemia.